Compared to afatinib treatment as the standard of care, there was a similar survival time in PFS of 1G EGFR-TKI in combination with chemotherapy (P = 0.709), which indicated that 1G EGFR-TKI in combination with chemotherapy might be a potentially effective option for the treatment of NSCLC patients with EGFR exon 18 mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.